Mirimus was established in 2010 with the goal of creating a scalable and cost effective pipeline for model generation by harnessing the power of RNAi and CRISPR technologies to develop animal models which are crucial for preclinical evaluation of new therapeutics. Through cutting edge technology, powerful predictive tools, and vital partnerships, Mirimus is paving the path to develop safer and more effective therapeutics by pin-pointing potential toxicities, validation, and disease modeling.

In 2020, responding to the Covid-19 pandemic, our team of experts mobilized their scientific expertise to develop a safe, regular, affordable, and non-invasive testing methodology. Our testing protocol, SalivaClear, is successful in detecting and monitoring SARS-COV-2 infection within communities around the country, allowing them to return to in-person operations. Mirimus’ goal is to facilitate the re-opening of the US economy by increasing access to testing and preventing large-scale outbreaks.